Ebola Hemorrhagic Fever, www.CDC.gov

Looming Pressure on Pharma as the Spread of Ebola Continues

When will a vaccine become available for Ebola? Killing over 8,000 people in West Africa since last year and still spreading, the need for a prophylactic Ebola vaccine is becoming increasingly important. Companies are racing to bring a safe vaccine to market and with the current pace of the epidemic in Liberia, Sierra Leone and Guinea, the demand for Ebola …

Merck enters the Ebola Vaccine Race in NewLink Partnership

Merck obtains the rights to NewLink genetics’ experimental Ebola Vaccine, putting pressure on GSK Merck has struck a agreement with NewLink Genetics to licence their investigational Ebola vaccine, rVSV-EBOV. The $50 million agreement gives Merck exclusive rights to develop, manufacture, and distribute the vaccine across the world. This partnership should allow NewLink to keep pace with the huge effort by …

Amongst the flurry of efforts to combat the West African Ebola outbreak, Johnson & Johnson is trying its hand at developing a vaccine

Johnson & Johnson To Fast Track Ebola Vaccine Trials

Amongst the flurry of efforts to combat the West African Ebola outbreak, Johnson & Johnson is trying its hand at developing a vaccine Johnson & Johnson can be counted amongst the ranks of yet another pharmaceutical company that has joined the race to develop an Ebola vaccine. Thus far, the most advanced vaccine candidate is Glaxo Smith Kline’s, which is the …

Ebola vaccine trials fast-tracked by international consortium

Unprecedented international consortium assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine August 28, 2014 A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of a series of safety trials of potential vaccines aimed at preventing the disease that has killed more than 1,400 people …

Ebola Vaccine Using Immunovaccine’s DepoVax Proves Highly Efficacious in Non-Human Primate Study

Ebola Vaccine Using Immunovaccine’s DepoVax Proves Highly Efficacious in Non-Human Primate Study August 25th, 2014 Immunovaccine Inc. (“Immunovaccine”) (TSX-V: IMV), a clinical stage vaccine company, today announced positive results for a vaccine formulated in its DepoVax™ technology in an Ebola virus challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). …

On the 7th of August 2014, Tekmira Pharmaceuticals Announced That the FDA has Allowed Potential Use of Their Experimental Ebola Drug on Infected Patients

Tekmira’s Lipid Nanoparticle (LNP) Technology Targeting Ebola Like Virus Highlighted in Scientific Publication

Data From Animal Model Demonstrates Complete Protection Three Days After Infection August 20th, 2014 Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced the publication of data in a peer-reviewed scientific journal which highlights positive results in an animal model of Marburg virus infection enabled by Tekmira’s lipid nanoparticle (LNP) technology. Tekmira, along with …

Ebola situation in Nigeria and Guinea: encouraging signs

August 19th, 2014 The outbreak of Ebola virus disease in west Africa continues to evolve, with cases confirmed in Guinea, Liberia, Nigeria, and Sierra Leone. At present, no cases have been confirmed anywhere else in the world outside these 4 countries. Nigeria The situation in Lagos, Nigeria, where the first imported case was detected in July, looks reassuring. At present, …